ThrasherIGRA: Diagnosis of Tuberculosis Infection in HIV Co-infected Children

Sponsor
Case Western Reserve University (Other)
Overall Status
Completed
CT.gov ID
NCT00541294
Collaborator
Thrasher Research Fund (Other)
250
1
37.3
6.7

Study Details

Study Description

Brief Summary

Background: The TB and HIV epidemics are closely linked in developing countries, where 450,000 children die from HIV annually. TB is a major cause of death in HIV-infected children and is reversing gains made in child survival.

The traditional tuberculin skin test (TST) has limited diagnostic accuracy for detecting TB infection. Adult studies suggest that new blood-based diagnostic TB testing offers a quicker, more accurate way to diagnose TB infection. Such diagnostic testing may directly guide clinical management and preventive strategies in immune-suppressed HIV-infected children, who are at high risk of becoming TB diseased following infection. Data regarding the usefulness of these tests in children is currently limited.

Objective(s) and Hypothesis(es): The investigators hypothesize that blood-based TB diagnostic testing can accurately identify children with TB infection. In a community with high rates of TB and HIV infection, the following specific aims will be investigated in HIV-infected and uninfected children:

  1. assess the agreement between the TST and blood-based diagnostic testing,

  2. compare the performance of the TST and blood-based diagnostic testing to a standardized history of TB exposure,

  3. measure the impact of age, nutritional and immune status on children's response to blood-based testing,

  4. describe factors that might modify children's response to testing over time, and 5) examine the effect of environmental exposures and previous vaccination on the TST, blood-based testing and other measures of immune responses to TB.

Potential Impact: The benefits of an accurate, rapid diagnostic test of TB infection in children include 1) timely institution of treatment for TB infection to prevent severe disease and mortality, and 2) preclusion of over diagnosis and treatment. Treatment of childhood TB infection also prevents future contagious adult disease, thus decreasing community transmission. Blood-based diagnostic testing may also be able to identify children that are more likely to become ill following TB infection. Therefore, blood-based diagnostic testing has great potential to improve TB control and the health of HIV-infected and uninfected children, their households and communities.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    250 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Diagnosis of Tuberculosis Infection in HIV Co-infected Children
    Actual Study Start Date :
    Jan 15, 2008
    Actual Primary Completion Date :
    Feb 22, 2011
    Actual Study Completion Date :
    Feb 22, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    B

    M.tb unexposed HIV-infected and uninfected children <15 years of age

    A

    M.tb exposed HIV-infected and uninfected children <15 years of age

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      3 Months to 15 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • age less than 15 years

      • completion of informed consent

      Exclusion Criteria:
      • less than 3 months of age

      • documented anemia

      • recent diagnosis of tuberculosis

      • receiving treatment for tuberculosis

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Despond TuTu TB Centre, Stellenbosch University Tygerberg Western Cape South Africa 07505

      Sponsors and Collaborators

      • Case Western Reserve University
      • Thrasher Research Fund

      Investigators

      • Principal Investigator: Anna M Mandalakas, MD, PhD, Baylor College of Medicine
      • Principal Investigator: Anneke C Hesseling, MD, MS, University of Stellenbosch

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Anna Maria Mandalakas, Professor, Baylor College of Medicine
      ClinicalTrials.gov Identifier:
      NCT00541294
      Other Study ID Numbers:
      • RES104272
      First Posted:
      Oct 10, 2007
      Last Update Posted:
      Jan 18, 2022
      Last Verified:
      Jan 1, 2022
      Keywords provided by Anna Maria Mandalakas, Professor, Baylor College of Medicine
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Jan 18, 2022